Cantor’s Mara Goldstein says growth beyond 2020 for CELG just got cloudy with the FDA’s RTF letter for ozanimod.
Celgene Corporation (NASDAQ:CELG) announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective …
